Regulatory CD4+ T Cells Expressing Endogenous T Cell Receptor Chains Protect Myelin Basic Protein–specific Transgenic Mice from Spontaneous Autoimmune Encephalomyelitis by Olivares-Villagómez, Danyvid et al.
 
1883
 
J. Exp. Med. 
 
Ó
 
 The Rockefeller University Press • 0022-1007/98/11/1883/12 $2.00
Volume 188, Number 10, November 16, 1998 1883–1894
http://www.jem.org
 
Regulatory CD4
 
1
 
 T Cells Expressing Endogenous T Cell
Receptor Chains Protect Myelin Basic Protein–speciﬁc
Transgenic Mice from Spontaneous Autoimmune
Encephalomyelitis
 
By Danyvid Olivares-Villagómez,
 
*
 
‡
 
 Yijie Wang,
 
*
 
 and Juan J. Lafaille
 
*
 
From the 
 
*
 
Division of Molecular Pathogenesis, Skirball Institute of Biomolecular Medicine, and the 
Department of Pathology, and the 
 
‡
 
Sackler Institute of Graduate Biomedical Sciences, New  York 
University Medical Center, New  York 10016
 
Summary
 
The development of T cell–mediated autoimmune diseases hinges on the balance between ef-
fector and regulatory mechanisms. Using two transgenic mouse lines expressing identical mye-
lin basic protein (MBP)–specific T cell receptor (TCR) genes, we have previously shown that
mice bearing exclusively MBP-specific T cells (designated T/R
 
2
 
) spontaneously develop ex-
perimental autoimmune encephalomyelitis (EAE), whereas mice bearing MBP-specific T cells
as well as other lymphocytes (designated T/R
 
1
 
) did not. Here we demonstrate that T/R
 
2
 
mice can be protected from EAE by the early transfer of total splenocytes or purified CD4
 
1
 
 T
cells from normal donors. Moreover, whereas T/R
 
1
 
 mice crossed with B cell–deficient, 
 
g/d
 
 T
cell–deficient, or major histocompatibility complex class I–deficient mice did not develop EAE
spontaneously, T/R
 
1
 
 mice crossed with TCR-
 
a
 
 and -
 
b
 
 knockout mice developed EAE with
the same incidence and severity as T/R
 
2
 
 mice. In addition, MBP-specific transgenic mice that
lack only endogenous TCR-
 
a
 
 chains developed EAE with high incidence but reduced sever-
ity. Surprisingly, two-thirds of MBP-specific transgenic mice lacking only endogenous TCR-
 
b
 
chains also developed EAE, suggesting that in T/R
 
1
 
 mice, cells with high protective activity
escape TCR-
 
b
 
 chain allelic exclusion. Our study identifies CD4
 
1
 
 T cells bearing endogenous
 
a
 
 and 
 
b
 
 TCR chains as the lymphocytes that prevent spontaneous EAE in T/R
 
1
 
 mice.
Key words: T helper cells • T cell receptor rearrangements • allelic exclusion • allelic
inclusion • autorreactivity
 
A
 
utoreactive CD4
 
1
 
 T cells are believed to play a major
role in chronic inflammatory diseases such as multiple
sclerosis, diabetes, and rheumatoid arthritis. However, the
mere presence of CD4
 
1
 
 autoreactive T cells is not suffi-
cient for development of autoimmune diseases (1), as a
number of investigators have detected self-antigen–specific
T cells in normal individuals (2–5). Moreover, the fre-
quency of such self-reactive T cells is often similar between
normal individuals and those afflicted with autoimmune
diseases. For instance, myelin basic protein (MBP)-reactive
 
1
 
T cells constituted 7.18 
 
6
 
 2.38% of T cell lines derived
from patients with multiple sclerosis, and 4.70 
 
6
 
 1.58% of
the T cell lines derived from normal individuals, a differ-
ence considered not significant (6). More surprisingly, even
in systems with an artificially high frequency of self-reactive
CD4
 
1
 
 T cells, such as TCR transgenic mice, only a small
proportion of mice develop spontaneous autoimmune dis-
eases under normal, pathogen-free conditions (7, 8). In the
latter cases, self-reactive T cells were shown to be gener-
ated in large numbers, migrated normally to the peripheral
lymphoid organs, and responded well to the self-antigen in
vitro and in vivo. Similar observations were reported by
Scott et al. (9) using another self-reactive TCR transgenic
mouse model in a BALB/c genetic background.
The presence of nontolerant self-reactive T cells in nor-
mal individuals and transgenic animals suggests a role for
regulatory cells. Thus, the development of autoimmune
disease depends not only on the generation of self-reactive
T cells, but also on the presence or absence of the appro-
priate number of functional regulatory cells.
 
1
 
Abbreviations used in this paper:
 
 
 
b
 
2m, 
 
b
 
2-microglobulin; EAE, experimental
autoimmune encephalomyelitis; KO, knockout; MBP, myelin basic pro-
tein; RAG-1, recombination activating gene-1; T/R
 
2
 
, MBP-specific T
cell receptor transgenic mice with mutated RAG-1 genes; T/R
 
1
 
, MBP-
specific T cell receptor transgenic mice with at least a normal RAG-1 gene.
  
1884
 
Regulatory CD4
 
1
 
 T Cells Prevent Spontaneous EAE
 
In several experimental and natural systems, T cell–
dependent autoimmune diseases appear to arise, paradoxi-
cally, as a consequence of immunodeficiency. For instance,
neonatal thymectomy induces multiple organ-specific au-
toimmune diseases (10, 11). One such disease, autoimmune
oophoritis, is caused by CD4
 
1
 
 effector cells and can be pre-
vented by transfer of normal splenocytes (12). The cells that
suppress disease have been characterized as CD4
 
1
 
/CD25
 
1
 
T cells (13, 14). Omenn’s syndrome, a Th2-induced au-
toimmune condition (15), was recently shown to be caused
by impaired activity of both recombination-activating gene
(RAG)-1 and RAG-2 proteins (16). In these two condi-
tions, alterations induced by neonatal thymectomy or im-
paired V(D)J recombination, respectively, may lead to a re-
duced generation of regulatory cells.
Modigliani et al. (17) showed, in a model of transplan-
tation, that mice receiving allogeneic thymic epithelium
accepted skin grafts of the same origin as the thymic epithe-
lium, but rejected third party skin grafts. Tolerance could
be transferred to nude recipient mice with total peripheral
lymphocytes or purified CD4
 
1
 
, but not CD8
 
1
 
, T cells. In-
terestingly, if only a small number of cells were transferred
from the tolerant host, regulatory cells could be lost, whereas
effector functions always remained (17). These examples in-
dicate that regulatory cells are relatively rare as compared
with effector cells. Therefore, after a general reduction in
lymphocyte numbers, the balance between the two cell types
is tilted in favor of effector cells and against regulatory cells.
We previously generated mice transgenic for the 
 
a
 
 and 
 
b
 
chains of an MBP-specific TCR (8). We showed that these
transgenic mice, designated T/R
 
1
 
, had a T cell repertoire
largely dominated by MBP-specific T cells in the periph-
eral lymphoid organs, and that these cells were not anergic.
Despite the lack of tolerance toward MBP, the vast major-
ity of T/R
 
1
 
 mice never developed experimental autoim-
mune encephalomyelitis (EAE) spontaneously. However,
when T/R
 
1
 
 mice were crossed with mice mutant for the
RAG-1 gene, all the mice (designated T/R
 
2
 
) developed
EAE spontaneously (8). Although the number of MBP-
specific T cells is roughly equal in T/R
 
1
 
 and T/R
 
2
 
 mice,
T/R
 
1
 
 mice bear, in addition, a low proportion of T cells
expressing TCRs encoded by the endogenous (nontrans-
genic) 
 
a
 
 and 
 
b
 
 TCR genes (hereafter referred to as endog-
enous 
 
a
 
 or 
 
b
 
 chains), 
 
g/d
 
 T cells, and normal numbers of B
cells. Due to the RAG-1 mutation (18), T/R
 
2
 
 mice con-
tain only MBP-specific T cells and no other lymphocytes.
Because the immune system of T/R
 
2
 
 mice is strictly
monoclonal, it was possible that spontaneous EAE in T/R
 
2
 
mice was triggered by cross-reactivity with components of
the normal microbial flora, which would become more ag-
gressive in the absence of an adaptive immune system.
However, the differences in EAE susceptibility between
T/R
 
2
 
 and T/R
 
1
 
 mice were reproduced in mice kept un-
der germ-free conditions (Lafaille, J.J., F. Van de Keere,
and S. Tonegawa, unpublished data). We therefore con-
cluded that lymphocytes present in T/R
 
1
 
 mice but absent
in T/R
 
2
 
 mice were responsible for the prevention of EAE
in T/R
 
1
 
 mice.
Using genetic ablation of lymphocyte populations as well
as adoptive transfer of total or purified subpopulations of
splenocytes, we here identify CD4
 
1
 
 T cells expressing en-
dogenous TCR chains as the cells that prevent EAE in T/R
 
1
 
mice.
 
Materials and Methods
 
Mice.
 
MBP-specific TCR transgenic mice have been de-
scribed previously (5). In brief, genomic clones of the TCR-
 
a
 
(V
 
a
 
4) and -
 
b
 
 (V
 
b
 
8.2) chains obtained from an encephalomyeli-
togenic CD4
 
1
 
 T cell clone (19) were microinjected into C57/
BL6 fertilized eggs. MHC H-2
 
u
 
 was introduced through breeding
with C57/BL10.PL mice (The Jackson Laboratory, Bar Harbor,
ME). To generate T/R
 
2
 
 mice in C57/BL genetic background,
RAG-1 KO mice (18) were backcrossed for nine generations
with C57BL/6 mice at Susumu Tonegawa’s laboratory (Mas-
sachusetts Institute of Technology [MIT], Cambridge, MA).
RAG-1 KO-C57/BL6 mice were then crossed with T/R
 
1
 
 mice
in a C57/BL genetic background. Similar procedure was fol-
lowed with TCR-
 
d
 
 KO mice (20), which were backcrossed
eight times with C57BL/6 mice at MIT. TCR-
 
a
 
 KO (21),
TCR-
 
b
 
 KO (21), 
 
b
 
2-microglobulin (
 
b
 
2m) KO (22), 
 
m
 
MT KO
(23), and IL-4 KO (24), all backcrossed with C57BL/6 were pur-
chased from The Jackson Laboratory. CD4 KO mice (25) back-
crossed with C57/BL6 were obtained from Dr. Dan Littman
(New York University Medical Center). B6.Thy1.1 mice were
purchased from The Jackson Laboratory and crossed with C57/
BL10.PL mice to yield H-2
 
u/u
 
 Thy1.1 animals in a C57/BL ge-
netic background. All mice were kept in the specific pathogen–
free facility at the Skirball Institute, New York University Medi-
cal Center.
 
Disease Evaluation.
 
EAE was scored as described by Baron et
al. (19): level 1, limp tail; level 2, weak or partial hind leg paraly-
sis; level 3, total hind leg paralysis; level 4, hind leg paralysis and
weak or partial front leg paralysis; level 5, moribund. All mice
were observed weekly for EAE level and general status of the
mice (e.g., weight). Moribund animals were killed. All proce-
dures involving mice were approved by New York University’s
Institutional and Animal Care Use Committee (IACUC).
 
Cell Sorting and Cell Transfer Experiments.
 
Donor splenocytes
from mice up to 6 wk of age were obtained by rupturing the
lymphoid organ following conventional procedures. Cells were
washed with PBS, counted, filtered through a nylon membrane,
and then injected intravenously. CD4
 
1
 
 cells were purified by
magnetically depleting CD8
 
1
 
 and B220
 
1
 
 cells using MACS mi-
crobeads and the magnetic cell separator VarioMACS (Miltenyi
Biotec Inc., Sunnyvale, CA). Purity of the separation was assessed
by FACS
 
Ò
 
 (Becton Dickinson, San Jose, CA) analysis (see below).
CD4
 
1
 
 cell purity was 
 
.
 
93%. Cells were adoptively transferred as
mentioned above.
 
Generation and Specificity of mAb 3H12.
 
Anti-MBP transgenic
TCR mAb 3H12 was generated by priming subcutaneously nor-
mal B10.PL (H-2
 
u/u
 
) mice with 2 
 
3 
 
10
 
7
 
 in vitro–cultured resting
transgenic MBP-specific T cells in complete Freund’s adjuvant.
Animals were subsequently boosted intravenously with 2 
 
3 
 
10
 
7
 
 in
vitro–cultured resting transgenic MBP-specific T cells or total
splenocytes from T/R
 
2
 
 mice. 3 d after the last immunization,
splenocytes from immune animals were fused with the myeloma
partner P3L1 and incubated in selection medium following stan-
dard procedures. Supernatants were then tested for their ability to
specifically stain MBP-specific transgenic T cells by FACS
 
Ò
 
. 
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The staining specificity of 3H12 is defined in the following
way: 3H12 stains MBP-specific T cells from the TCR transgenic
mice, but does not stain cells from either nontransgenic syngeneic
mice (see Fig. 5 
 
A
 
), or D011.10 TCR transgenic mice (data not
shown), which, like the MBP-specific TCR transgenic mice, ex-
press V
 
b
 
8.2. Moreover, 3H12 recognizes neither the transgenic-
encoded 
 
a
 
 chain paired with any endogenous 
 
b
 
 chain, nor the
transgenic-encoded 
 
b
 
 chain paired with any endogenous 
 
a
 
 chain.
The former was concluded after we observed no 3H12 staining
on T cells derived from a cross between TCR-
 
a
 
 KO mice and a
mouse strain that is transgenic only for the MBP-specific TCR-
 
a
 
chain (data not shown). The latter was concluded because some
endogenous V
 
a
 
-expressing T cells in T/
 
a
 
1
 
b
 
2
 
 mice (which can
only express the transgenic-derived 
 
b
 
 chain) are negative for
3H12 staining (see Fig. 5 
 
B
 
). We have not ruled out the possibil-
ity that the 3H12 antibody stains, in addition to the MBP-specific
TCR, a subpopulation of cells expressing the transgenic-encoded
 
b
 
 chain paired with selected endogenous 
 
a
 
 chains that are struc-
turally related to the transgenic-encoded TCR-
 
a
 
 chain.
Other Antibodies, Cell Reconstitution, and FACSÒ Analysis.
3H12 was generated as described in the preceding section. Anti-
TCR Vb4, Vb7, and Vb10b antibodies were purchased from
Caltag Labs. (Burlingame, CA). All other antibodies were pur-
chased from PharMingen (San Diego, CA). Recipient mice were
bled (50 ml each time) through the retro-orbital plexus using a
small capillary tube. Blood was stained with anti-CD4, anti-CD8,
anti-B220, anti-Thy1.1, and anti-Thy1.1 antibodies. TCR Vb
and a usage was determined by staining peripheral blood with
3H12, anti-Thy1.1, anti-CD3, and the anti-TCR antibodies
against Vb2-, -Vb3-, -Vb4-, -Vb6-, -Vb7-, -Vb8.1.2-, -Vb8.3-,
Vb9-, -Vb10b-, -Vb11-, -Vb13-, -Vb14-, -Va2-, -Va3.2-,
-Va8-, and Va11. To determine the proportion of CD81 T cells
and g/d T cells in donor-derived and recipient splenocytes, cells
were stained with anti-CD8, anti-CD4, anti-TCR-g/d, 3H12,
and anti-B220 antibodies. Peripheral blood was stained for 45
min at room temperature with the antibody cocktail, lysed, and
fixed with FACSÒ lysing solution (Becton Dickinson), and then
washed twice with PBS. When biotinylated antibodies were
used, an additional 20 min of incubation in the presence of
Streptavidin (PharMingen) was included. Samples were resus-
pended in PBS and analyzed in a FACScaliburÒ instrument (Bec-
ton Dickinson) equipped with two lasers. Unless otherwise indi-
cated, up to 5,000 lymphocytes were acquired. For endogenous T
cell repertoire analysis of T/a2b1, T/a1b2, T/a2b2 and T/a1b1
mice, at least 50,000 lymphocytes were acquired. Splenocytes
were stained similarly with incubations at 48C, and no incubation
in lysis solution. Samples were washed in staining solution (PBS,
2% fetal calf serum, 0.1% NaN3), and resuspended in the same so-
lution. Propidium iodide was included in the solution to gate out
dead cells. Up to 20,000 lymphocytes were acquired.
Results
Transfer of Splenocytes Protects T/R2 Mice from EAE.
We have shown previously that MBP-specific TCR trans-
genic mice crossed with RAG-1 KO mice spontaneously
develop EAE (8). At that time, the genetic makeup of these
mice was comprised of three strains. Therefore, individual
mice differed in minor histocompatibility antigens and cell
transfer experiments could not be performed without a po-
tential graft versus host reaction. To eliminate this problem,
we crossed the T/R1 mice (originally made in C57BL oo-
cytes) with RAG-1 KO mice that had been backcrossed for
nine generations into the C57BL background. All T/R2
mice in the C57BL background also developed EAE spon-
taneously (Fig. 1 A). However, the disease onset was accel-
erated, with z80% of the C57BL mice first exhibiting signs
of EAE by the age of 60 d, and all mice developing EAE by
90 d of age. In contrast, we only observed signs of EAE in
one of the 70 T/R1 littermates included in this study, and
this mouse did not display the first signs of EAE until the
age of 130 d. This low EAE incidence was observed only in
T/R1 animals heterozygous for the TCR transgenes. T/R1
mice homozygous for the TCR transgenes develop EAE
spontaneously (our unpublished data), and the 14% inci-
dence of spontaneous EAE in T/R1 mice that we initially
reported reflects the inclusion of some animals homozy-
Figure 1. Total splenocytes from normal donors protect T/R2 mice
from spontaneous EAE. (A) EAE incidence in untreated B10.PL H-2u/u
T/R2 (u; n 5 9) and T/R1 (s; n 5 70). Data indicate the percentage of
mice that developed EAE within each group. (B) 3-wk-old T/R2 mice
were transferred with 107 (s and ---; n 5 3) or 106 (m; n 5 3) total sple-
nocytes from normal donors (Thy1.1), or left untreated (u; n 5 9). Mice
were observed for a period of 150 d and EAE was scored as described in
Materials and Methods. Data represent the average of each group. (C)
Thy1.11 T cell reconstitution was followed biweekly in T/R2 mice
treated as in B (107: s, n 5 3; 106: n, n 5 3) by staining of peripheral
blood from recipient mice with anti-Thy1.1-PE and anti-Thy1.2-FITC
antibodies. Data represent the average of each group. (D) TCR Vb ex-
pression in the donor-derived population 150 d after transfer of 107 total
splenocytes into T/R2 (black bars) or RAG-1 KO (white bars) mice. Data
from one mouse per group is shown. (E) T/R2 mice were treated with
107 total normal splenocytes before 31 (n; n 5 3), at 35 (d; n 5 4), and
between 43 and 45 (u; n 5 4) d after birth, or treated with PBS between
31 and 45 days (---). Data represent the average of the groups.1886 Regulatory CD41 T Cells Prevent Spontaneous EAE
gous for the TCR transgenes. All work described hence-
forth pertains to mice on the C57BL background, with
MHC H-2u/u and heterozygous for the TCR transgenes.
To study the regulation of spontaneous EAE, we intra-
venously transferred 106 and 107 total splenocytes from
normal Thy1.1 mice into 3-wk-old T/R2 (Thy1.2) recipi-
ents. Administration of 106 splenocytes had a protective ef-
fect on T/R2 mice, as EAE onset was delayed, its severity
diminished, and the animals recovered from the disease
(Fig. 1 B). An even more dramatic protective effect was
observed upon injection of 107 splenocytes (Fig. 1 B). Al-
though mice receiving either 106 or 107 normal splenocytes
were both free of EAE at the end of the observation period,
the beneficial effect of 106 normal splenocytes was clearly
delayed in comparison to that of 107 normal splenocytes.
To monitor the repopulation of recipient mice by the
donor-derived T cells, we used the allotypic marker Thy-
1.1. Repopulation of the B cell compartment could be
monitored by direct staining with anti-B220 antibodies,
since T/R2 mice lack mature B cells. Blood samples were
obtained approximately every 12 d for a period of 150 d,
and stained for Thy1.1, Thy1.2, CD8, CD4, and B220.
Donor-derived T cells plateaued at z6% of the total circu-
lating T cells in mice injected with 106 splenocytes. In con-
trast, after injection of 107 splenocytes, donor-derived T
cells expanded continuously, reaching 30% of the circulat-
ing T cells 150 d after injection (Fig. 1 C). Repopulation
by B cells was modest in all recipient mice when compared
with that of T cells. The proportion of lymphocytes ex-
pressing B220 at 150 d was only 4.5 and 1%, respectively,
in T/R2 mice receiving 107 and 106 splenocytes (data not
shown). However, those recipients in which donor-derived
T cells expanded the best also supported greater expansion
of B cells.
Analysis of lymphocyte compartments in individual mice
revealed no strict correlation between the expansion of do-
nor-derived cells and EAE protection. In some cases, fully
protected animals displayed slightly lower proportions of
donor-derived lymphocytes than animals afflicted with a
mild form of the disease. Therefore, the protection of T/R2
mice from EAE is not determined only by the quantity of
donor-derived lymphocytes.
Because T cells expanded considerably more than B cells
in the recipient mice, we investigated whether particular
donor-derived T cell subpopulations were enriched in the
protected recipients as compared with recipients in which
T cell expansion is independent of EAE protection. To-
ward that end, we determined whether the Vb usage of T
cells recovered from T/R2 mice that had been protected
from EAE differed from that of T cells recovered from
nontransgenic RAG-1 KO recipients. No major skewing
on the TCR Vb usage was observed (Fig. 1 D), indicating
that protection from EAE does not entail a large expansion
of T cells bearing particular Vb chains.
Based on these results, we conclude that normal spleno-
cytes are able to protect T/R2 mice from EAE. The pro-
tection is more effective as more cells are injected, but does
not always correlate with the degree of expansion of the
donor-derived cells within the recipient mice.
Older T/R2 Mice Are Less Susceptible to Protection by Sple-
nocytes than Younger Mice. The experiments described in
the preceding section were performed using 21-d-old
mice. To determine the effectiveness of splenocyte cell
transfer in older T/R2 mice, 107 normal splenocytes were
injected into 31-, 35-, and 43–45-d-old T/R2 recipients
that had not yet developed EAE. The protective effect of
the transferred cells decreased as the age of the recipients
increased (Fig. 1 E). Younger recipients (31 d old) either
showed no disease, or only mild disease with delayed onset
followed by complete recovery (no sequelae). In contrast,
older recipients (43–45 d old) had no delay in the onset of
EAE and frequently did not recover completely. However,
some beneficial effects of splenocyte injection were appar-
ent even when animals were injected at 43–45 d of age.
Table 1. Splenocytes from mMT KO Mice but not from CD4 KO Mice Confer Protection from EAE
Treatment* n
Mice
without EAE‡ Maximum EAE Total recovery§ Final EAEi
CD81 cells
reconstitution¶
g/d1 cells
reconstitution¶
3 3 106 CD4 KO 7 0/7 2.4 6 1.36 1/7 1.5 6 1.7 ND ND
2 3 106 CD4 KO 5 0/5 2.4 6 0.5 0/5 1.9 6 0.5 0.2 0.03
3 3 106 mMT KO 3 2/3 0.7 6 1.2 0/1 0.2 6 0.3 ND ND
2 3 106 mMT KO 5 2/5 0.8 6 0.8 2/3 0.2 6 0.3 0.4 0.02
PBS 4 0/4 2.8 6 1.5 0/4 2.5 6 1.7 ND ND
T/R2 mice (,31 d old) transferred with different numbers of CD4 KO or mMT KO splenocytes, or injected with PBS. Mice were observed for a
period of 140 d and EAE was scored as described in Materials and Methods.
*Injected cells correspond to the number of total CD81 cells.
‡Observed mice with no signs of EAE.
§Observed mice that recovered completely from EAE.
iAverage EAE score at the end of the experiment.
¶Number of CD81 or g/d1 cells per one anti-MBP-specific TCR transgenic cell after 140 d of treatment.1887 Olivares-Villagómez et al.
Due to the effect of age on the effectiveness of protec-
tion by cell transfers, all subsequent experiments were car-
ried out using recipients ,31 d old.
CD41 T Cells Protect T/R2 Mice from EAE. The major
populations of lymphocytes in the spleen are B cells, CD41
T cells, CD81 T cells, g/d T cells, and NK T cells. To es-
tablish which cell type(s) was more important in protecting
T/R2 mice from EAE, we transferred total splenocytes
from H-2u/u CD4 KO mice and mMT KO mice back-
crossed into the C57BL background. Due to the mutation
in the CD4 coreceptor, CD4 KO mice display reduced T
helper activity (25, 26), whereas mMT KO mice lack ma-
ture B cells (23). Cell injections were normalized according
to the number of CD81 T cells. As shown in Table 1,
transfer of splenocytes from mMT KO animals protected
against EAE very effectively. In a total of eight recipients,
four never developed EAE, two that did develop disease
recovered completely, and the remaining two had only a
mild form of EAE at the end of the experiment. In con-
trast, all 12 mice that received splenocytes from CD4 KO
mice developed EAE, with only 1 mouse recovering com-
pletely. However, compared with PBS-injected T/R2
mice, there was a small protective effect of splenocytes
from CD4 KO mice at the end of the experiment.
Since T/R2 animals that received splenocytes from
mMT KO mice did not develop EAE, B cells can be ex-
cluded from acting as the protective lymphocytes. In addi-
tion, because the numbers of CD81 cells and g/d T cells
were equal in the protective (mMT KO) or nonprotective
(CD4 KO) inoculum, and similar in the recipient mice at
the end of the experiment (Table 1), we can also exclude
CD81 T cells and g/d cells. These data suggest that CD41
T cells are the protective lymphocytes.
To demonstrate that CD41 T cells themselves are protec-
tive, and do not act indirectly through, for example, CD81
T cells, we transferred 5 3 106 magnetically sorted CD41 T
cells from normal mouse spleens into T/R2 mice. CD41 T
cells had a clear protective capacity (Fig. 2). Of the 11 T/R2
mice injected with purified CD41 T cells, 7 (64%) re-
mained disease free, whereas all of the PBS-injected mice
developed EAE. Similar results were obtained with mature
single positive CD41 thymocytes (data not shown). There-
fore, we conclude that CD41 T cells present in normal
individuals have the capacity to prevent the development
of EAE in T/R2 mice, independently of CD81 T cells or
B cells.
IL-4 Is Not Required for Protection of T/R2 Mice. CD4
KO mice have z15% of the number of helper T cells
found in normal mice, as determined by expression of a
human CD2 cDNA regulated by CD4 cis-acting sequences
(27).
Although generally deficient in helper T cell activity,
some helper T cell responses are unaffected in CD4 KO
mice, particularly Th1 responses (28). On the other hand,
Th2 responses are severely impaired in these mice (29).
To determine whether the lack of protection by CD4
KO splenocytes was caused by their inability to mount Th2
responses, we transferred total splenocytes from IL-4 KO
mice into T/R2 mice. Although IL-4 KO mice are known
to be defective in Th2 responses, splenocytes from these
mice were found to have a protective capacity similar to
that of IL-4–normal littermates (Fig. 3), indicating that
conventional Th2 responses are not necessary for protec-
tion against EAE in T/R2 mice.
Mice Lacking Endogenous TCR-a or -b Chains Develop
EAE Spontaneously. The spontaneous EAE phenotype
was originally described comparing unmanipulated T/R1
and T/R2 mice. To confirm that CD41 T cells with en-
dogenous TCR rearrangements are the lymphocytes that
prevent EAE in T/R1 mice, we crossed T/R1 mice with
mMT KO (lacking B cells), b2m KO (lacking MHC class
I–restricted T cells, such as CD81 and NK T cells), TCR-d
KO (lacking g/d T cells), and TCR-a/b KO (lacking en-
dogenous TCR-a and -b chains) mice. All the KO mice
had been backcrossed repeatedly onto the C57BL back-
ground.
As predicted by the cell transfer experiments, MBP-
specific TCR transgenic mice that congenitally lack B
cells, CD81 T cells, CD1-restricted NK T cells, and g/d T
cells do not develop EAE (Table 2). To assess the role of
endogenous TCR-a and -b chains in EAE protection, we
generated MBP-specific TCR transgenic mice lacking en-
dogenous TCR-a chains (referred to as T/a2b1), lacking
endogenous TCR-b chains (T/a1b2), and lacking both
TCR-a and -b chains (T/a2b2), and compared them to
mice which have at least one wild-type allele at both the
TCR-a and b loci (T/a1b1). These four kinds of mice
were generated from the same type of breeding pairs, in
which MBP-specific transgenic males heterozygous for
both  a and b TCR mutations were crossed with nontrans-
Figure 2. Purified CD41 T
cells protect T/R2 mice from
spontaneous EAE. Total spleno-
cytes from normal mice were
depleted of CD81 T cells and
B cells with anti-CD8 and
anti-B220 magnetic beads (see
Materials  and Methods). 5 3 106
purified CD41 T cells were trans-
ferred into T/R2 mice (u; n 5
11). As a control, age- and sex-
matched mice were treated with
PBS (---; n 5 3). Data represent
the average of each group.
Figure 3. Splenocytes from
IL-4 KO mice protect T/R2
mice from spontaneous EAE as
effectively as do splenocytes from
IL-41 mice. T/R2 mice were
transferred with 107 total spleno-
cytes from IL-4 KO (s; n 5 4)
or IL-41 ( u; n 5 5) mice, or
were treated with PBS (---; n 5
4). Data represent the average of
each group.1888 Regulatory CD41 T Cells Prevent Spontaneous EAE
genic females homozygous for the mutations at both the
TCR-a and -b loci. Mice were scored for EAE once a
week for a period of at least 4 mo.
None of the 32 T/a1b1 mice developed EAE sponta-
neously. In contrast, all 16 T/a2b2 mice and 19 out of 20
T/a2b1 mice developed EAE spontaneously. Interest-
ingly, 15 out of 21 T/a1b2 mice also developed EAE,
whereas the remaining 6 mice were completely free of
clinical signs of EAE for at least 5 mo (Table 2). Because
we expected that some T/a1b2 mice would be heterozy-
gous for the TCR-a KO mutation whereas others would
be homozygous for the wild-type TCR-a locus, we specu-
lated that the six healthy animals might be homozygous for
the wild-type TCR-a allele. This homozygosity could en-
able the mice to have a greater diversification of the endog-
enous TCR-a repertoire. However, this prediction was
not confirmed: although two of the healthy mice had the
wild-type allele in both chromosomes, the remaining four
mice were heterozygous for the TCR-a mutation (data
not shown). The EAE susceptibility of T/a1b2 mice was
unexpected, because allelic exclusion is highly effective at
the TCR-b locus (30).
Further analysis of disease in a subgroup of the above
T/a2b2, T/a2b1, T/a1b2, and T/a1b1 mice revealed
that the mean EAE score in mice lacking either one of the
endogenous TCR chains (T/a2b1 or T/a1b2) was re-
duced in comparison to mice lacking both endogenous
TCR chains (T/a2b2). These latter mice behaved simi-
larly to T/R2 mice (Fig. 4).
The reduction of the mean EAE score in T/a2b1 or
T/a1b2 animals could reflect a delayed onset of EAE in
some mice, and/or a less severe disease. In the case of
T/a2b2 mice, 13% of mice developed EAE by day 50 af-
ter birth, 87% of the mice had EAE by day 60 after birth
(Table 3), and none of the mice with EAE showed im-
provement of more than one clinical level during the ob-
servation period. Analysis of 17 T/a2b1 mice showed that
only 8 animals (47%) first displayed clinical signs of EAE
before 60 d of age (Table 3). Analysis of 18 T/a1b2 mice
indicated that only 7 (39%) of these animals had EAE be-
fore 60 d of age, whereas 6 mice did not develop EAE even
up to 5 mo of age (Table 3). In summary, many animals
unable to generate either of the endogenous TCR-a or -b
chains showed a delayed onset of EAE, which was more
pronounced in T/a1b2 than in T/a2b1 mice. Interest-
ingly, 3 out of 17 T/a2b1 mice, and 3 out of 18 T/a1b2
mice, developed EAE before 50 d of age, a proportion similar
to that found in T/a2b2 or T/R2 animals. Thus, T/a2b1
and T/a1b2 mice displayed a greater variance in the age of
EAE onset. Mortality was also reduced in T/a2b1 and
T/a1b2 animals: 5 out of 15 T/a2b2 mice died as a con-
sequence of EAE, whereas none of T/a2b1 or T/a1b2
animals did (Table 3). Finally, T/a2b1 and T/a1b2 mice
experienced a delay in disease onset as well as reduced disease
severity and mortality in comparison with T/a2b2 mice.
T Cell Repertoire Analysis of T/a2b1, T/a2b1, and
T/a1b1 Mice. Since T/a2b1, T/a1b2, T/a2b2, and
T/a1b1 mice differ only in their capacity to express TCR
chains encoded by the endogenous TCR-a or -b genes,
the differences in EAE susceptibility that we observed be-
tween the various kinds of mutant mice must be attributed
to differences in the a/b T cell repertoire. Depending on
the kind of TCR transgenic mice, the a/b T cell repertoire
may consist of up to four types of cells: (a) cells expressing
exclusively the transgene-encoded MBP-specific TCR
(at-gbtg); (b) cells expressing a transgenic chain paired with an
endogenous chain (atgbend or aendbtg); (c) cells expressing both
a and b chains not encoded by the transgenes (aendbend); and
(d) cells expressing the transgene-encoded a/b chains in ad-
dition to a TCR chain encoded by the endogenous loci
(double-expressing cells).
To correlate the EAE susceptibility with the T cell reper-
toire, we stained peripheral blood samples of T/a2b1, T/
a1b2, T/a2b2, and T/a1b1 mice with an anti-TCR clo-
notypic antibody (3H12; for a description of its specificity see
Materials and Methods), together with anti-CD3 and a panel
of anti-TCR Va and Vb antibodies. The data is shown in
Fig. 5 and the results are summarized in Table 4. We ob-
served that the number of TCR clonotype-negative cells was
z2% in 6–8-wk-old T/a1b1 mice, 0.6% in T/a2b1 mice,
0.2% in T/a1b2 mice, and 0.1% in T/a2b2 mice (Fig. 5 A
and data not shown). The proportion of clonotype-negative
cells was relatively constant among mice of the same geno-
type and age, and increased as the animals aged.
Using four different anti-TCR Va antibodies that stain
21% of the T cells in wild-type syngeneic mice, we ob-
Table 2. EAE Incidence in the Offspring of Anti-MBP 
TCR-specific Transgenic Mice Crossed into Different
KO Backgrounds
Anti-MBP TCR transgenic
RAG-11 mice crossed into
Mice with EAE/
mice observed
TCR-a2b2 16/16
TCR-a2b1 19/20
TCR-a1b2 15/21
TCR-a1b1 0/32
TCR-d KO 0/26
b2m KO 0/18
mMT KO 1/19
Figure 4. T/a2b1 and T/a1b2
mice develop less severe EAE
than T/a2b2 mice. T/a2b2
(u; n 5 16), T/a2b1 (s; n 5
18), T/a1b2 (e; n 5 19), and
T/a1b1 mice (3; n 5 22) were
monitored for spontaneous EAE
as described in Materials and
Methods.1889 Olivares-Villagómez et al.
served staining of z2% of the T cells in both T/a1b1 and
T/a1b2 young mice. Therefore, z10% of the T cells in
both types of mice express endogenous TCR-a chains.
The vast majority of T cells expressing endogenous Va
chains coexpress the MBP-specific a/b TCR (Fig. 5 B),
whereas most T cells expressing endogenous Vb chains are
negative for the MBP-specific TCR (Fig. 5 C). An exam-
ple of Va2 and Vb6 staining of the same group of mice as
in Fig. 5 A is shown in Fig. 5 D.
In summary, although T/a2b1 mice have slightly more
MBP-TCR2 T cells than T/a1b2 mice, they lack T cells
coexpressing endogenous b chains with the transgene-
encoded TCR. On the other hand, the repertoire diversity in
T/a1b2 mice is provided largely by cells that coexpress the
MBP-specific TCR and endogenous TCR-a chains. Finally,
the repertoire diversity in disease-free T/a1b1 mice is pro-
vided by both MBP-TCR2negative cells and double-
expressing T cells. We conclude that the susceptibility of
T/a2b1, T/a1b2, T/a2b2, and T/a1b1 mice to EAE cor-
relates inversely with the diversity of their T cell repertoire.
Table 3. Longitudinal Analysis of Spontaneous EAE in TCR-a/b Mutant Mice
Strain n Observed EAE*
EAE onset
before day 50‡
EAE onset
before day 60‡
EAE onset
before day 90‡
Mortality due
to EAE§
T/a2b2 15 15 2 (13.3) 13 (86.6) 15 (100) 5 (33.3)
T/a2b1 17 16i 3 (17.6) 8 (47) 13 (76.5) 0
T/a1b2 18 12 3 (16.6) 7 (38.8) 9 (50) 0
*Number of mice that developed EAE during the 160 d of observation.
‡Mice that developed EAE during the indicated time frame. Percentage is indicated in parentheses.
§Mice that died of EAE during the course of the experiment. Percentage is indicated in parentheses.
iThe only mouse that did not develop EAE died at 4 mo of age.
Figure 5. Repertoire analysis of T/a1b1, T/a1b2, T/a2b1, and nontransgenic mice. (A) Peripheral blood from a group of 6-wk-old littermates was
stained with anti-CD3 and the anti-TCR clonotypic mAb 3H12. The double-expressing cells are contained in the middle gate. (B) Blood from one T/a1b2
mouse (different than the ones in A) was stained for Va2, CD3, 3H12, and CD4. CD3 and Va2-positive lymphocytes are shown. (C) Blood from one
T/a2b1 mouse (different than the ones in A) was stained for Vb6, CD3, 3H12, and CD4. CD3 and Vb6 positive lymphocytes are shown. (D) Anti-
CD3 and anti-Vb6 (top) or Va2 (bottom) blood staining from the same mice as shown in A. Note that most Va2-positive cells in the T/a1b1 and
T/a1b2 samples are off the diagonal, indicating that these cells express two TCR-a chains (36, 52). At least 50,000 lymphocytes were acquired.1890 Regulatory CD41 T Cells Prevent Spontaneous EAE
Discussion
We have used genetic depletion and adoptive transfer
methods to identify a lymphocyte population, present in
T/R1 mice and absent in T/R2 mice, capable of prevent-
ing EAE. Both approaches indicate that CD41 T cells have
a protective effect on spontaneous EAE. A similar conclu-
sion has been reached in the paper by Van de Keere et al.
appearing in this issue (29a).
a/b T Cells Bearing Endogenous Receptors Are Required for
Protection against Spontaneous EAE. MBP-specific TCR trans-
genic mice that congenitally lack B cells, CD81 T cells,
CD1-restricted NK T cells, or g/d T cells do not develop
spontaneous EAE (Table 2), indicating that none of these
absent cell types is the primary protective cell population in
our experimental model. However, mice lacking T cells
that express endogenous a and b TCR chains do sponta-
neously develop EAE. In conjunction with adoptive trans-
fer experiments, these results demonstrate that CD41 T
lymphocytes bearing endogenous a or b T cell receptors
protect T/R1 mice from EAE.
In TCR transgenic mice, expression of transgenic TCR-b
chains leads to allelic exclusion of endogenous TCR-b
chains (30), whereas expression of transgenic TCR-a chains
does not. However, further rearrangement of endogenous
TCR-a chains is halted after positive selection (31, 32).
Therefore, in a positively selecting MHC environment,
most TCR transgenic mice bear a T cell repertoire domi-
nated by the transgene-encoded specificity, with most of
the endogenously derived repertoire comprised of cells ex-
pressing the transgenic b chain paired with endogenous a
chains (for review see reference 33).
Crosses of T/R1 mice with TCR-a KO and TCR-b
KO mice generated three main observations. First, sponta-
neous EAE develops in 100% of mice lacking both endog-
enous TCR chains (T/a2b2) and is almost as high in mice
lacking only endogenous a chains (T/a2b1). In contrast,
one-third of mice lacking endogenous b chains (T/a1b2)
never show signs of EAE, and mice capable of generating
both endogenous TCR chains never develop EAE. Sec-
ond, the age of EAE onset in T/a2b2 mice is similar to
that observed in T/R2 mice, with 80% of the mice showing
first signs of EAE within a 2-wk period. On the other hand,
the age of EAE onset in T/a2b1 and T/a1b2 animals fol-
lows a much broader distribution (Table 3). Finally, EAE
severity and mortality are greater in afflicted T/a2b2 mice
than in T/a2b1 and T/a1b2 animals (Table 3 and Fig. 4).
To understand these observations, we have begun examin-
ing the endogenous TCR repertoire in T/a2b1, T/a1b2,
and T/a1b1 mice. MBP clonotype–negative T cells com-
prise z2% of total T cells in young (6-wk-old) T/a1b1
animals,  z0.6% in T/a2b1 mice, z0.2% in T/a1b2
mice, and z0.1% in T/a2b2 mice. Further TCR diversity
is provided by cells coexpressing MBP-specific TCR with
endogenous TCR-a chains. These coexpressing cells com-
prise z10% of the total T cell population in both T/a1b2
and T/a1b1 mice. On the other hand, we observed only a
small proportion of cells coexpressing endogenous TCR-b
chains and the MBP-specific TCR, and therefore the rep-
ertoire diversity of T/a2b1 mice is largely provided by cells
that do not express the MBP-specific clonotype. The po-
tential for TCR diversity is therefore greatest in T/a1b1
mice, followed by T/a1b2 mice, then T/a2b1 mice, and
finally T/a2b2 mice (Table 4).
Despite the relatively equal proportions of T cells express-
ing endogenous TCR-a chains in T/a1b1 and T/a1b2
mice, the incidence of EAE in these two groups is very
different. Thus, it is likely that T cells bearing TCRs con-
sisting of two endogenous TCR chains (aendbend) are the
most effective at achieving EAE protection. For instance,
although ,2% of the T cells in young T/a1b1 mice ex-
press both endogenous TCR-a and b chains, these cells are
sufficient to induce long-lasting protection in all mice.
Some degree of protection is also conferred by T cells ex-
pressing endogenous TCR-a chains with transgenic-derived
TCR-b chains (aendbtg), since one-third of the T/a1b2,
but none of the T/a2b2 mice, remained free of EAE.
On the other hand, T cells expressing the MBP-specific
transgenic-encoded a chain with endogenous b chains
(atgbend) appear to have a very low protective capacity.
However, as atgbend cells constitute a very small proportion
of total T cells in T/a2b1 mice, the possibility exists that
atgbend T cells could confer protection were they present in
higher numbers. Adoptive transfer experiments with sorted
subpopulations of CD41 T cells from T/a2b1, T/a1b2,
and T/a1b1 should clarify this point.
Stochastic Generation of Regulatory Cells May Determine the
EAE Outcome of T/a1b2 Mice. It is remarkable that, of
the T/a1b2 mice, approximately one-third developed an
early, severe EAE, one-third developed a late form, and
one-third did not develop EAE at all. The increased heter-
ogeneity in the age of EAE onset was also observed, albeit
to a lesser extent, in T/a2b1 mice (Table 3). This variabil-
ity contrasts sharply with the relatively homogeneous behav-
Table 4. Repertoire Diversity in the Different TCR-a/b KO Mice*
T/a2b2 T/a2b1 T/a1b2 T/a1b1
TCR-clonotype negative cells 0.1% 0.6% 0.2% 2.0%
Double-TCR expressing cells 0% ,0.1% z10% z10%
*6-wk-old mice were analyzed.1891 Olivares-Villagómez et al.
ior of T/a2b2 and T/a1b1 mice, and can not be explained
by differences in the genetic makeup of the T/a1b2 mice,
since all KO mice were backcrossed several times into a
C57BL background.
The presence of a single TCR-b chain in T/a1b2 mice
restricts the potential diversity of the T cells, since en-
dogenous TCR-a chains have to pair appropriately with
the transgenic b chain. In addition, positive selection of
MBP-specific T cells, which prevents further TCR-a rear-
rangements (31), is very effective in H-2u/u mice. These
two factors generate a highly restrictive environment for
the rearrangement and selection of endogenous TCR-a-
encoded chains, a situation that enables important reper-
toire variations between genetically identical individuals.
The resulting biased T cell repertoire may bear T cells ex-
pressing TCRs with poor, intermediate, or good avidity to
putative ligands required for the activation of regulatory
cells. Based on our data, approximately one-third of the
T/a1b2 mice appear to successfully generate those rare
CD41 aendbtg cells and one-third may be unable to gener-
ate those cells, at least at a young enough age to prevent
disease. The remaining third of T/a1b2 animals may gen-
erate regulatory cells with low avidity for the required
ligand, resulting in ineffective regulation and a later onset
of EAE. A similar explanation can be applied to the behav-
ior of T/a2b1 mice. However, the need for endogenous
TCR-a chains seems to be more important than the need
for endogenous TCR-b chains for ligand recognition, be-
cause all but one T/a2b1 mice developed EAE (Table 2).
The endogenous TCR repertoire of individual T/a1b2
and T/a2b1 mice in connection to EAE susceptibility is
currently under investigation.
Is Allelic Inclusion of TCR-a Chains Protective? Recently,
Sarukhan et al. (34) described a pathogenic role for T cells
expressing two TCR-a chains in a TCR transgenic mouse
diabetes model. In adoptive transfer experiments, T cells
expressing endogenous TCR-a chains and low levels of
transgenic-encoded TCR-a chains were shown to be
more diabetogenic than those expressing high levels of the
transgenic-encoded (autoreactive) TCR, which did not
express endogenous TCR-a chains. There are several dif-
ferences between this diabetes model and our model of
EAE. In EAE, elimination of endogenous TCR and Ig
gene-rearrangements dramatically increases the frequency
of disease, whereas the same changes in the diabetes model
produce the opposite effect (35). The reduction in the inci-
dence of diabetes may reflect the fact that other cell types
(such as CD81 T cells) are required to trigger disease in this
experimental model. It has also been shown that T cells ex-
pressing endogenous TCR-a chains are not required for
the initiation of disease in another TCR transgenic diabetes
model (36). Furthermore, the relatively low incidence of
diabetes observed in TCR transgenic mice heterozygous
for the selecting MHC H-2g7 increased upon crossing those
mice with TCR-a KO mice (36).
Due to the presence of T cells coexpressing endogenous
TCR-a chains with the MBP-specific TCR in H-2u/u
T/a1b1 mice, which do not develop EAE, and their ab-
sence in T/a2b1 and T/a2b2 mice, which do, it is possi-
ble that allelic inclusion of a second TCR on MBP-specific
cells would, actually, make the mice less susceptible to
EAE. This is unlikely for the following reasons. First, al-
though it is possible that MBP-specific cells coexpressing
endogenous TCR-a chains have a higher threshold of acti-
vation than cells expressing only the MBP-specific TCR,
the majority of MBP-specific T cells would have to be
double expressors in order for an increased activation
threshold to affect the incidence of EAE, which is clearly
not the case. In addition, transfer of normal CD41 cells
does protect T/R2 mice from EAE in the absence of en-
dogenous TCR chains on the MBP-specific cells. Finally,
two out of three T/a1b2 mice develop EAE despite bear-
ing similar numbers of T cells that coexpress endogenous
TCR-a chains and the MBP-specific receptor as the dis-
ease-free T/a1b1 mice.
Lymphocytes Other Than the Primary Regulatory CD41 T
Cells May Modulate EAE at Later Stages. EAE onset and se-
verity differ between T/a2b2 mice and T/a2b1 or T/a1b2
mice. As previously stated, we believe that the develop-
ment of EAE is due to a lack of primary regulation by
CD41 T cells. On the other hand, the lower morbidity and
mortality observed in T/a2b1 and T/a1b2 mice as com-
pared with T/a2b2 mice could be due to lymphocytes
other than the CD41 primary regulatory cells. In various
EAE models it has been shown that B cells (37), CD81 T
cells (38–40), and CD41 T cells expressing Vb14 and, to a
lesser extent, Vb3 (41, 42), are involved in the recovery
from acute EAE or in the control of relapses. Importantly,
if B cells ameliorate the course of spontaneous EAE, they
do so in an a/b T cell–dependent manner, because none of
these beneficial effects are apparent in T/a2b2 mice,
which behave very similarly to T/R2 mice. We are cur-
rently crossing the T/a2b1 and T/a1b2 with mMT KO
mice and b2m KO mice to investigate the possible “sec-
ondary” protective role of cells absent in those mutant
mice.
Regulatory Function of CD41 T Cells. Splenocytes from
CD4 KO mice conferred virtually no protection to T/R2
mice. Helper activity is not abolished in CD4 KO mice,
but Th2 responses are (29). However, the lack of protec-
tion by splenocytes from CD4 KO mice is not due to defi-
cient Th2 responses, because splenocytes from IL-4 KO
mice effectively prevented EAE. Based upon these data, it
is tempting to speculate that the regulatory cells need high
avidity interactions with MHC-class II ligands, and this
avidity level cannot be reached in the absence of CD4. Al-
ternatively, the generation of regulatory cells in CD4 KO
mice may be impaired due to holes in the T cell repertoire.
Several reports have linked CD41 T cell populations
with immune regulation. In rat EAE models, CD41 T cells
with suppressive potential were isolated at the time of re-
covery from this monophasic disease (43, 44). These cells
were shown to secrete TGF-b (45). A regulatory type of
CD41 T cell (named Th3) was obtained after oral immuni-
zation with low doses of MBP (46). MBP-induced Th3
cells secreted large amounts of TGF-b, and, upon cell1892 Regulatory CD41 T Cells Prevent Spontaneous EAE
transfer, protected against EAE induced both by MBP and
proteolipid protein. The protective effect of Th3 cells
could be abolished with anti–TGF-b treatment. Female
nonobese diabetic mice and BB rats develop diabetes spon-
taneously, which can be prevented by early transfer of
CD41 T cells (47, 48). In a mouse colitis model, CD41
CD45RB-low T cells have been shown to have regulatory
activity, whereas CD45RB-high T cells were pathogenic
(49). This effect was also mediated by TGF-b (50). Re-
cently, CD41 T regulatory cells (named Tr1) secreting
large amounts of IL-10 were described (51). Tr1 cells were
capable of preventing colitis in an adoptive transfer system,
an effect mediated synergistically by IL-10 and TGF-b.
Therefore, it is possible that the CD41 regulatory cells that
we describe here also protect T/R1 mice from EAE
through the secretion of immunomodulatory cytokines
such as TGF-b and/or IL-10.
Because of the 100% incidence of spontaneous EAE and
the relatively synchronized manner in which it arises in the
C57BL genetic background, T/a2b2 mice or T/R2 mice
display features not found in any other spontaneous au-
toimmunity model. In addition, this experimental system
enables the clear identification of MBP-specific effector T
cells in mixtures with other lymphocytes, and makes dis-
ease prevention possible upon adoptive transfer of purified
subpopulations of lymphocytes, two important require-
ments for the further characterization of regulatory T cells.
In this report we show that protection from EAE can be
accomplished without a large expansion of donor-derived
cells, and that expression of both endogenous TCR-a and
-b chains in CD41 T cells is required for full protection
from the disease. However, the question of whether CD41
regulatory T cells act through specific ligand recognition,
or competition for growth factors and space, remains a ma-
jor unresolved issue and is the subject of ongoing studies.
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